Protocol No
GOG-3018-VBL-VB-111-701
Principal Investigator
William Bradley
Phase
III
Summary
The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer
Description
To assess how well the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer as measured by Overall Survival.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
ClinicalTrials.gov